SEC Form 5 · accession 0001387131-18-000678
Adamis Pharmaceuticals Corp · ADMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eddie Wabern Glover
Officer — CEO of U.S. Compounding, Inc.
Period of report
Dec 31, 2017
Accepted (ET)
Feb 14, 2018 · 7:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000887247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 15, 2017 | G | 41,666 | $0.00 | D | 783,334 | D | |
| Common Stock | Nov 2, 2017 | G | 41,666 | $0.00 | D | 783,334 | D |
Table II — derivative securities
No Table II lines on this filing.